Acute Myeloid Leukemia Refractory

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Natural Killer-cell Therapy for Acute Myeloid Leukemia

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

Venetoclax to Augment Epigenetic Modification and Chemotherapy

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

CD123 Redirected T Cells for AML in Pediatric Subjects

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

Lentivirally Redirected CD123 Autologous T Cells in AML

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Study of REM-422 in Patients With AML or Higher Risk MDS

Off-the-shelf CD123 CAR-NK for R/R AML

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)